- Category: HBV Treatment
- Published on Wednesday, 25 April 2012 00:00
- Written by Liz Highleyman
HIVandHepatitis.com coverage of the 2012 International Liver Congress -- 47th Annual Meeting of the European Association for the Study of the Liver (EASL), April 18-22.
Conference highlights include experimental hepatitis C therapies, interferon-free regimens, boceprevir (Victrelis) and telaprevir (Incivek/Incivo) in real-world practice, difficult-to-treat patients, HIV/HCV coinfection, hepatitis B research, and liver cancer research.